Clinical trial · no report yet · Phase 1

COBALT-RCC trial (CTX130): what clinicians have said so far

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

NCT04438083 ↗
Terminated
CRISPR Therapeutics AG
Standard size, estimated: 151–300 verified statements once built

We haven't built an HCP commentary report on COBALT-RCC (CTX130 in advanced clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on COBALT-RCC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
11 posts on X, typically up to 48 once built
2 YouTube videos, typically up to 9 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Phase: Phase 1
Status: Terminated
Conditions: Renal Cell Carcinoma
Interventions: CTX130
Arms: CTX130 · Experimental
Enrollment: 19
Primary outcomes: Part A (dose escalation): Incidence of adverse events
Part B (cohort expansion): Objective response rate
Sponsor: CRISPR Therapeutics AG
Start: Jun 16, 2020
Primary completion: Oct 8, 2024
Results posted: No
Registry record: NCT04438083 · updated Jan 8, 2025

Publications

linked from the registry

Dewulf J, Flieswasser T, Delahaye T, Vangestel C, Miranda A, de Haard H, Jacobs J, Smits E, Van den Wyngaert T, Elvas F. Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. EJNMMI Radiopharm Chem. 2023 Apr 24;8(1):8. doi: 10.1186/s41181-023-00194-3. PubMed 37093350

Get this report

Standard

Report, built on orderBuilt within 24 hours of confirming your order: $1,250

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on COBALT-RCC so far

Reports on the same drug or indication

The trial

Publications